Dmitriy Zamarin on Dealing With Side Effects from T-VEC Treatment in Melanoma
Dmitriy Zamarin, MD, PhD, assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses side effects that nurses should look our for when treating patients with the T-VEC virus.
Dmitriy Zamarin, MD, PhD, assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses side effects that nurses should look our for when treating patients with the T-VEC virus.
T-VEC, which is approved for the treatment of melanoma, is an oncolytic virus that Zamarin says typically has little side effects for patients. The most common effects are inflammation at the injection site or a fever, both of which are signs that the immune system is working. However, it is possible to get a bacterial infection at the injection site, which would be something that the patient would need to seek care from the nurse or doctor for.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
